Announcements Trials

Browse Landscape

Phase

Phase 2 22 Phase 1 20 Phase 1/2 18 Phase 3 11 Phase NA 9 Phase 4 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Neoplasms 24 Prostatic Neoplasms 21 Multiple Myeloma 18 Carcinoma, Non-Small-Cell Lung 15 Carcinoma, Hepatocellular 15 Stomach Neoplasms 11 Papillomavirus Infections 11 Lung Neoplasms 11 Colorectal Neoplasms 11 Melanoma 9 Neoplasm Metastasis 7 Leukemia, Myeloid, Acute 7 Waldenstrom Macroglobulinemia 6 Pain, Postoperative 6 Lymphoma, Non-Hodgkin 6 Leiomyoma 6 Hematologic Neoplasms 6 Brain Neoplasms 6 Thyroid Neoplasms 5 Smoking Cessation 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Polycystic Ovary Syndrome 5 Pain 5 Lymphoma 5 Glioma 5 Carcinoma, Renal Cell 5 Venous Thromboembolism 4 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4

Interventions

olaparib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Carcinoma, Ovarian Epithelial × 1 year × Clear all

NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡